病毒发病机制的 ART 调节-猫眼课题宝

病毒发病机制的 ART 调节

批准号：

10609801

负责人：

Dirk P Dittmer

金额：

$36.93万

依托单位：

UNIV OF NORTH CAROLINA CHAPEL HILL

依托单位国家：

美国

项目类别：

财政年份：

2007

资助国家：

美国

项目状态：

未结题

起止时间：

2007-05-15 至 2025-04-30

来源：

https://reporter.nih.gov/project-details/10609801

关键词：

AIDS clinical trial group Acquired Immunodeficiency Syndrome Affect Basic Science Biological Assay Biology CD4 Lymphocyte Count Cells Cercopithecine Herpesvirus 1 Clinical DNA Disease Endothelial Cells Epigenetic Process Funding Genetic Transcription Goals HIV HIV Seronegativity HIV Seropositivity HIV/AIDS Human Human Herpesvirus 4 Human Herpesvirus 8 Immune Immunosuppression Interruption Kaposi Sarcoma Lesion Long-Term Effects Malignant Neoplasms Messenger RNA MicroRNAs Mission Molecular Mouth Diseases National Institute of Dental and Craniofacial Research Nelfinavir Oral Oral cavity Outcome Palate Kaposi&apos s Sarcoma Patients Persons Pharmaceutical Preparations Protease Inhibitor Public Health Publications Regimen Reporting Research Resources Risk Role Route Saliva Sampling Severity of illness Shock Stratification Vertical Disease Transmission Viral Viral Load result Viral Pathogenesis Virus antiretroviral therapy clinical application clinical investigation co-infection comorbidity epigenome exosome extracellular vesicles improved low and middle-income countries oral HIV patient safety programs response transmission process

项目摘要

项目成果

Dirk P Dittmer的其他基金

相似基金

相关文献

中文摘要

翻译

项目摘要摘要在美国，大多数感染人类免疫缺陷病毒1型的患者都是长期的(10年以上) 联合抗逆转录病毒疗法(CART)。虽然CART将HIV复制抑制在50拷贝/毫升以下，但不是 CART对卡波西肉瘤相关疱疹病毒(KSHV)口服的长期疗效已知很多传播、口腔和全身性KS病或潜伏的KSHV水库。我们建议调查这一影响不同CART成分对KSHV和KS病的影响及长期阻断口服KSHV的目的传播和治愈艾滋病毒/艾滋病感染者的病毒。具体地说，我们将专注于调制 KSHV的重新激活以及CART药物如何影响KSHV外体/细胞外小泡。这是一场竞争激烈的响应PA-16-426/“高”或“中”优先艾滋病研究的续签申请--非艾滋病定义或艾滋病定义癌症(R01)。

英文摘要

Project Summary Abstract The majority of human immune deficiency virus 1 infected patients in the US are on long-term (10+ years) combination antiretroviral therapy (cART). While cART suppresses HIV replication to below 50 copies/ml, not much is known about the long-term effect of cART on Kaposi sarcoma associated herpesvirus (KSHV) oral transmission, oral and systemic KS disease or the latent KSHV reservoir. We propose to investigate the impact that different cART components have on KSHV and KS disease with the long-term aim to interrupt oral KSHV transmission and cure the virus from persons living with HIV/AIDS. Specifically, we will focus on modulating the reactivation of KSHV and how cART drugs affect KSHV exosomes/ extracellular vesicles. This is a competitive renewal application in response to PA-16-426/ "High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers (R01).

期刊论文(18)

专著(0)

科研奖励(0)

会议论文